BRIEF

on Affluent Medical (isin : FR0013333077)

Affluent Medical Bolsters Team with Key Appointments

On March 11, 2025, Affluent Medical, a French clinical-stage medtech company, announced three key leadership appointments to strengthen its market access strategy. Dr. Howard C. Herrmann and Pr. Nicolas Barry Delongchamps have been appointed as Chief Medical Officers (CMO) for the Structural Heart and Urology Platforms, respectively. Dr. Herrmann, an interventional cardiologist, and Pr. Delongchamps, a skilled urologist, will guide advancements in their specialized areas, focusing on innovative devices like the KALIOS mitral ring and the ARTUS urinary sphincter.

In tandem, Federica Azzimonti joins as Director of Clinical Operations, enhancing operational readiness for imminent clinical trials. With 25 years of experience, Federica will oversee trial execution, ensuring seamless implementation. According to CEO Sébastien Ladet, these appointments mark a critical growth phase as Affluent Medical progresses towards commercializing its advanced medical solutions.

R. P.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Affluent Medical news